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Abstract
For many years, the standard of treatment for hepatitis C virus (HCV) infection was a combination of pegylated
interferon alpha (Peg-IFN-α) and ribavirin for 24–48 weeks. This treatment regimen results in a sustained virologic
response (SVR) rate in about 50 % of cases. The failure of IFN-α-based therapy to eliminate HCV is a result of multiple
factors including a suboptimal treatment regimen, severity of HCV-related diseases, host factors and viral factors. In
recent years, advances in HCV cell culture have contributed to a better understanding of the viral life cycle, which has
led to the development of a number of direct-acting antiviral agents (DAAs) that target specific key components of viral
replication, such as HCV NS3/4A, HCV NS5A, and HCV NS5B proteins. To date, several new drugs have been approved for
the treatment of HCV infection. Application of DAAs with IFN-based or IFN-free regimens has increased the SVR rate up
to >90 % and has allowed treatment duration to be shortened to 12–24 weeks. The impact of HCV proteins in response
to IFN-based and IFN-free therapies has been described in many reports. This review summarizes and updates
knowledge on molecular mechanisms of HCV proteins involved in anti-IFN activity as well as examining amino
acid variations and mutations in several regions of HCV proteins associated with the response to IFN-based
therapy and pattern of resistance associated amino acid variants (RAV) to antiviral agents.
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Background
Hepatitis C virus (HCV) belongs to the Hepacivirus
genus which is part of the Flaviviridae family. HCV is a
small enveloped virus with a positive single-stranded
RNA genome containing approximately 9,600 nucleo-
tides which encodes for a large polyprotein of about
3,000 amino acids. The polyprotein precursor is cleaved
by the host and viral proteases into three structural
proteins (core, E1, E2) and seven nonstructural proteins
(p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B) [1, 2] (Fig. 1).
HCV core protein is a highly conserved RNA-binding
protein, which presumably forms the viral nucleocapsid
and plays a role in pathogenesis [3–5]. E1 and E2 enve-
lope glycoproteins are essential components of the HCV
virion and necessary for viral entry and fusion [6, 7]. P7
could act as a calcium ion channel and has an important
role in viral maturation and release [8, 9]. NS2 is a trans-
membrane protein required for NS2/3 autoprotease
activity that cleaves the site between the NS2 and NS3
junction [10–12] while NS3 is the protease and NTPase/
helicase [13, 14]. NS4A serves as a cofactor of the NS3
protease activity and NS4B functions as a membrane
anchor for the replication complex [15, 16]. NS5A is a
hydrophilic phosphoprotein needed for viral replication
[17, 18]. NS5B, a RNA-dependent RNA polymerase
(RdRp), is a key enzyme for viral replication promoting
synthesis of new RNA genomes [19, 20]. With the lack
of a proof-reading activity and error correction mecha-
nisms of the viral RdRp, the high genetic variability and
high degree of mutation rate of the HCV are occurred,
allowing for rapid adaptation and lead to a genetically
variant pool of viruses within the infected individual
[21, 22]. Due to the diversity of the genome, HCV is
classified into 7 major genotypes and 67 subtypes [23].
HCV genotypes are distributed in different parts of the
world. Genotypes 1–3 are widely distributed through-
out the world, genotypes 1 and 2 are endemic in West
Africa while genotype 3 is endemic in India. Genotypes
4 and 5 are prevalent in Africa and genotype 6 in
Southeast Asia. The distribution of genotype 7 has not
been fully evaluated [24, 25].
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Life cycle of HCV includes entry into the host cell,
uncoating of the viral genome, translation of viral pro-
teins, polyprotein processing, viral genome replication,
assembly and release of virions. All these events occur
outside the nucleus of the host cell [26]. Following initial
binding of the HCV particle to the host cellular recep-
tors, scavenger receptor class B member 1 (SRB1) [27]
and CD81 [28] via the E2 glycoprotein, the particle
engages in further interactions with several entry factors
including tight junction proteins claudin 1 (CLDN1)
[29], occludin (OCLN) [30], epidermal growth factor
receptor (EGFR), the ephrin receptor [31], and finally
enters cells by receptor-mediated endocytosis. The viral
RNA genome is released into the cytoplasm and subse-
quently translated at the rough endoplasmic reticulum
(ER). After translation, the viral proteins, in conjunction
with host cell factors, induce the formation of a mem-
branous web where the RNA genome replication occurs
[26]. The positive sense RNA genome is generated
through a negative strand intermediate and is packaged
into the viral particle containing the core and envelope
proteins which accumulates to the ER and lipid droplets
[32]. HCV virions are presumably formed by budding
through the ER, or an ER derived compartment, and are
exited the cell via the secretory pathway [33].
HCV infection occurs globally and remains a serious
health problem worldwide. Nowadays, about 150 million
people, representing 2–3 % of the world’s population,
are chronically infected with HCV and more than
350,000 people die from HCV-related liver diseases each
year [34]. The severity of HCV infection ranges from a
mild illness to a serious sickness that leads to chronic
hepatitis, liver cirrhosis and hepatocellular carcinoma
(HCC). Only a minority of HCV-infected patients can
clear the virus spontaneously during acute infection [35].
Innate immune responses are the first line of defense
against viral infections and interferons (IFNs) are im-
portant cytokine responsible for the induction of an
antiviral state of the cells for elimination of HCV during
acute infection [36]. However, the majority of patients
are unable to clear the virus. Approximately 50–80 % of
acute HCV infections persist and progress into chronic
infection and approximately 4–20 % of patients with
chronic hepatitis C develop liver cirrhosis within 10–20
years. Annually, about 1–5 % of patients with cirrhosis
are at risk of developing HCC” [35]. The viral persist-
ence is related to both host and viral factors. The virus
has developed several strategies to escape host innate
immune responses by different mechanisms [37]. The
mechanisms that protect HCV from IFN-mediated
innate immune reactions are not completely understood,
but involve interruption of IFN induction pathway, IFN-
stimulated genes (ISGs) production, or direct antagon-
ism of effector systems by viral proteins [37, 38]. A
protective vaccine for HCV infection is not available yet
and although therapeutic options are improving they are
still limited as well as some patients still resist to the
treatment. Development and improvement of antiviral
therapies and effective vaccines are still needed.
Treatment of HCV infection and rate of response
For many years, the combination of IFN-α and ribavirin
was the approved treatment regimen for chronic HCV
infection. IFNs are a family of cytokines released by host
cells in response to various stimuli including virus infec-
tion. IFNs induce expression of multiple antiviral ef-
fector proteins working against virus replication [36].
IFN-α therapy leads to a rapid decline in HCV RNA
Fig. 1 HCV genomic organization, HCV proteins and targets for direct-acting antiviral agents. The HCV genome, having approximately 9.6 kilobases
(kb), contains a 5'-nontranslated region (NTR), an internal ribosome entry site (IRES), a long open reading frame encoding polyprotein precursor of
about 3,000 amino acid residues and a 3'-NTR. The polyprotein precursor is processed by both host and viral enzymes to release functional structural
and non-structural proteins. HCV NS3/4A, HCV NS5A, and HCV NS5B are targets for antiviral agents [1, 2]
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levels in serum [39, 40]. Ribavirin is a nucleoside analogue
and possesses activity against several RNA and DNA vi-
ruses, however, the exact mechanism of action of ribavirin
against HCV is still unknown [41]. The combination of
IFN-α and ribavirin therapy led to great improvements in
SVR rates [42–44].
Further improvement was achieved by the development
of pegylated interferon alpha (Peg-IFN-α), in which a large
molecule of polyethylene glycol is covalently attached to
recombinant IFN-α resulting in an active molecule with a
longer half-life, better pharmacokinetic profile, and better
rate of virologic response [45, 46]. The commercially avail-
able forms of IFN-α used for hepatitis C (α2a, α2b and
consensus IFN) have somewhat different potencies in vitro
but appear to yield similar response rates in treated pa-
tients [47, 48]. For patients who are chronically infected
with HCV, the former standard of care recommendation
was to use Peg-IFN-α plus ribavirin for 48 weeks for pa-
tients infected with genotype 1 or 24 weeks for patients
infected with genotype 2 or 3 and for genotypes 4, 5 and
6, it has been suggested that patients were treated in a
similar manner as those for patients with genotype 1 [46].
This treatment regimen led to SVR rates ranging from 42
to 46 % in patients infected with genotype 1, 76–80 % in
patients infected with genotype 2 or 3, and 50–77 % in pa-
tients infected with genotypes 4, 5, and 6 [48–50]. Overall
sustained responses occur in about one-half of patients
but the likelihood of response varies greatly, depending
on viral and host characteristics [51, 52]. The key host
factors associated with response to IFN include IL28B
genotype, race, and fibrotic stage [53, 54] while viral
load and viral genotype are important viral factors associ-
ated with SVR [52, 54]. In addition, many problems asso-
ciated with IFN-based regimens such as considerable side-
effects, expense, and length of treatment lead to many pa-
tients not being able to tolerate the full course of treat-
ment, leading to treatment failure [55].
Since 2011, a number of direct acting antiviral agents
(DAAs), which specifically target hepatitis C viral pro-
teins including NS3/4A, NS5A and NS5B, have been
used to improve the treatment of HCV infection. First
generation NS3/4A protease inhibitors, including tela-
previr and boceprevir, were approved by the United
States Food and Drug Administration (FDA) for HCV
genotype 1 infection in 2011 [56–59]. Both compounds
were approved as triple combinations with Peg-IFN-α
and ribavirin, and this regimen increased SVR rates in
HCV genotype 1 infected patients to 66–75 % among
patients who had not previously received treatment for
their infection (treatment-naïve) and 59–64 % in patients
who had not responded to previous treatment (treatment-
experienced) [56–60]. A second-generation NS3/4A pro-
tease inhibitor, simeprevir [61], was approved in 2013. By
using simeprevir in combination with Peg-IFN-α and
ribavirin, the rates of SVR in treatment-naïve HCV
genotype 1 infected patients were 75–85 % [62–64].
Several NS5A inhibitors have been reported such as
ledipasvir (formerly GS-5885) [65], ombitasvir, formerly
known as ABT-267 [66], and daclatasvir (BMS-790052)
[67]. Ledipasvir and daclatasvir were approved in 2014 for
use in combination with sofosbuvir (NS5B inhibitor).
Triple therapy with Peg-IFN-α, ribavirin, and the NS5A
inhibitor daclatasvir led to SVR in 59–100 % of treatment-
naïve HCV genotype 1 and 4 infected patients, according
to drug dosage and HCV genotype [68].
There are 2 types of NS5B inhibitors, nucleoside/
nucleotide analogs and non-nucleotide analogs. Nucleo-
tide analogs such as mericitabine [69] and sofosbuvir
[70] act as false substrates for the HCV-RdRp and this
leads to chain termination after being incorporated into
the newly synthesized viral RNA [71, 72], and non-
nucleotide analogs, such as dasabuvir [73] bind to sev-
eral discrete sites on the NS5B polymerase, which leads
to conformational protein changes. Sofosbuvir was ap-
proved in 2013 as part of a combination treatment with
IFN and ribavirin and demonstrated extraordinary effi-
cacy for treatment-naïve patients infected with HCV
genotype 1 and 4 with 90 % of SVR rate [74–76]. The
use of triple IFN-containing regimens with the DAAs is
associated with side effects that can be severe. The IFN-
free regimens have been further considered by using a
combination of several DAAs with or without ribavirin.
For example, the combination of sofosbuvir plus ribavi-
rin in genotype 2 infected patients for 12 weeks showed
an SVR rate of about 95–97 % [77].
In October 2014, the FDA approved Harvoni as the
first DAA combination drug that does not require
administration in combination with interferon or ribavi-
rin. This daily, single tablet drug consists of the NS5A
inhibitor (ledipasvir) and the NS5B polymerase inhibitor
(sofosbuvir). In phase III clinical trials which enrolled
1,518 participants including treatment-naïve, treatment-
experienced and patients with cirrhosis, it was shown
that these groups of patients achieved an SVR rate of
between 96 and 99 % within 12–14 weeks of the admin-
istration of the drug [78, 79]. This new IFN-free therapy
allows for a simplified and shortened therapy duration
to 12–24 weeks for all HCV genotypes.
HCV proteins which mediate IFN resistance
IFNs are cytokines which are part of the host’s natural
immune response to the presence of pathogens, such as
viruses, bacteria, parasites or tumor cells [36]. After the
binding of IFNs to their specific receptors on the target
cell surface, an intracellular signaling cascade, the Janus
kinase (Jak) and signal transducer and activator of tran-
scription (STAT) pathway is activated. This leads to the
up-regulation of a number of IFN-stimulated genes
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(ISGs) and expression of multiple antiviral effector pro-
teins to eradicate the virus [80–82] (Fig. 2). IFN-α was
first shown to have beneficial effects in patients with
chronic HCV infection in 1986 [40] and has been used
for treatment of HCV infection until now. The failure of
IFN-α-based treatment to eradicate HCV infection is
influenced by multiple factors [51, 54]. It is believed that
host factors and viral factors, particularly viral load and
HCV genotype are important factors contributing to the
difference in response to the IFN therapy [83]. HCV
genotype 1 infected patients achieve poorly sustained
rates of response (42–52 %) to IFN-α-based therapy
compared to those infected with HCV genotypes 2 and 3
(78–86 %) [52]. So far, it has been suggested that several
HCV proteins are responsible for the inhibition of the
antiviral effects of IFN-α [84]. The expression of the
whole HCV polyprotein as well as single HCV proteins
of core, E2, NS3/4A, NS4B or NS5A have been shown
to antagonize the antiviral effect mediated by IFN-α in
many different ways as summarized in Fig. 2.
HCV core
The core protein of HCV interferes with the IFN signal-
ing pathway. It has been shown that the HCV core
induced the expression of the suppressor of the cytokine
signaling protein 3 (SOCS-3) and SOCS-1 in cultured
cells, which in turn antagonized IFN-α action by block-
ing the Jak/STAT pathway and the expression of ISGs
[85, 86]. The effect of core protein on the down-regu-
lated expression of IFN-induced antiviral genes was de-
scribed [87]. Additionally, the inhibitory effects of the
HCV core protein on IFN-induced phosphorylation and
nuclear translocation of STAT1 in cell cultures were
demonstrated. The HCV core protein binds directly to
STAT1, suggesting a model by which the binding of
HCV core to STAT1 resulted in the decrease of STAT1
phosphorylation and disruption of ISGs transcription
[88, 89].
HCV E2
The E2 protein of HCV was reported to be involved in
mediating IFN-α resistance through the inhibition of
protein kinase R (PKR) [90]. HCV E2 contains a peptide
of eight amino acids that are identical to a sequence in
PKR, four of which act as autophosphorylation sites in
PKR. Next to this region, E2 contains another consecu-
tive stretch of four amino acids identical to the phos-
phorylation site of the eukaryotic initiation factor 2
alpha subunit (eIF2α) [82]. This region is known as the
PKR-eIF2α phosphorylation homology domain (PePHD).
Binding of the PePHD derived from HCV genotype 1 to
the cellular PKR abolishes its kinase activity and blocks
its inhibitory effect on protein synthesis in vitro [90].
This may lead to viral protein translation taking place
during virus infection and IFN treatment. However,
these effects were not detectable for PePHD sequences
derived from HCV genotypes 2 and 3. It has been
hypothesized that the interaction of the PePHD with the
PKR may result in a relatively enhanced resistance of
HCV-1 isolates to IFN-α-based antiviral therapy [90].
HCV NS3/4A
The HCV protease disrupts the innate immune response
and IFN induction pathway. IFNs are induced in the
presence of the HCV viral genome sensing by pattern-
recognition receptors, retinoic acid inducible gene I
Fig. 2 Classical pathways of type I IFN induction and HCV mediating IFN resistance. HCV dsRNA is detected by the retinoic acid inducible gene I
(RIG-I) and the toll-like receptor 3 (TLR3) and subsequently triggers the cascade of adaptor proteins, mitochondrial antiviral signaling protein (MAVS)
and TIR-domain containing adapter-inducing interferon-β (TRIF), respectively. This leads to the activation of the type I IFN induction pathway. Binding
of IFNs to their cellular receptors activates an intracellular signaling cascade via the Jak/STAT signaling pathway and leads to the up-regulation of a
number of interferon-stimulated genes (ISGs) expression [80–82]
Kumthip and Maneekarn Virology Journal  (2015) 12:217 Page 4 of 12
(RIG-I) and toll-like receptor proteins (such as TLR3)
[37, 91]. It was shown that HCV NS3/4A protease
cleaves host proteins including the mitochondrial anti-
viral signaling protein (MAVS) [92, 93], and the TIR-
domain containing adapter-inducing interferon-β (TRIF)
[94], adaptor proteins of RIG-I and TLR3 signaling path-
ways, respectively. This leads to inhibition of the innate
immune response and the IFN induction pathway. The
HCV NS3/4A protein has also been shown to block the
phosphorylation and nuclear translocation of the inter-
feron regulatory factor 3 (IRF-3), a key component of
the downstream signal of both RIG-I and TLR3 resulting
in a significant reduction of the transcription of IFN-α-
inducible genes [95, 96].
HCV NS4B
It has been shown that the expression of HCV NS4B in
cell culture inhibited the protection of the cells by IFN-α
treatment from vesicular stomatitis virus infection. The
NS4B protein of HCV reduced the IFN-α-induced phos-
phorylation level of STAT1 and the expression levels of
type I interferon receptors and a reporter driven by the
IFN-stimulated response element (ISRE) promoter [97].
HCV NS5A
The NS5A protein of HCV binds to and inactivates PKR
in vitro. This binding is dependent on the PKR binding
domain (PKRBD, codons 2209–2274) [98, 99]. This
interaction presumes to allow viral protein synthesis to
occur during IFN treatment. A number of studies have
demonstrated the inhibitory effects of HCV NS5A pro-
tein on the IFN-induced Jak/STAT signaling pathway
[100–103]. It has been shown that HCV NS5A blocked
the ISRE promoter activity and IFN-induced STAT1
phosphorylation and its nuclear translocation resulted in
inhibition of the IFN-induced ISGs expression [100, 101,
103]. It has been proposed that the interaction between
the C-terminal region of NS5A and STAT1 is respon-
sible for the anti-IFN activity of NS5A [102, 103].
Amino acid variations associated with the
response to IFN-based therapy
In addition to the study of how HCV proteins counter-
act IFN activity, cloning and sequencing approaches for
HCV isolates derived from patient sera with known viro-
logic responses to antiviral therapy have been investi-
gated. The clinical importance of amino acid variability
within several functional regions of HCV proteins such
as core, E1, E2, NS3, NS4B, NS5A and NS5B in correl-
ation with the responses to IFN therapy have been
described [104–143].
HCV core
The significance of amino acid mutations in the core
protein of HCV and the response to IFN-based therapy
has been described well in genotype 1b. Previous studies
have demonstrated that substitutions of amino acid resi-
dues 70 (R70Q) and/or 91 (L91M) in the core region
were significant factors independently associated with a
non-virological response (NVR) to IFN and ribavirin
combination therapy [104, 105]. Substitutions in this
region were also used for predicting the response to IFN
in Japanese patients with HCV genotype 1b [106]. More-
over, the HCV core mutants R70 and L91 were shown to
be resistant to IFN in vitro. Theses mutants were asso-
ciated with a decrease in IFN-induced phosphorylation
of STAT1 and STAT2, and the expression of ISGs
through enhancement of the expression of SOCS-3 and
interleukin 6 [107, 108].
HCV E1/E2
Several studies have demonstrated that mutations within
the PePHD of the E2 protein of HCV genotypes 1b and
3a showed no correlation with the clinical outcomes in
patients treated with IFN-α [109–112]. However, it has
been demonstrated that PePHD of genotypes 2a and 2b
had multiple amino acid variations and one particular
motif, “RGQQ-” at the N-terminus of PePHD showed a
close relationship with IFN resistance [113]. Another
study showed that the presence of substitutions in a
N-terminal variable region (codons 617–641) in the C-
terminal region of E2 showed a significant correlation
with a low viral load and a sustained response to IFN
treatment [114]. Furthermore, a study into recombin-
ant 1a and 3a HCV genotypes identified that amino
acid substitutions at positions 345 and 348 of E1 and
414 of E2 increased IFN-α resistance [115]. It was
shown that amino acid changes I348T in E1 protein of
HCV genotype 1a (H77), F345V in E1 and V414A in
E2 of genotype 3a (S52) increased viral fitness and that
I348T and F345V/V414A mutants enhanced viral entry
and release, respectively [115].
HCV NS3
In the HCV replicon system, several mutations within
the NS3 gene that led to the enhancement of replica-
tion efficiency have been reported. The HCV isolates
from patients harboring amino acid substitutions in the
NS3 protein (R1283G, P1112R, and S1496M) showed a
slower decrease of HCV RNA than those without muta-
tions at those positions during IFN-α-based therapy
[116]. Additionally, it has been reported that the HCV
1b-infected patients with a better anti-IFN response
(>3.5 log decline of viral RNA by day 28) have higher
number of amino acid substitutions in the NS3 protein
than those of the patients with a poor response (<1.4 log
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decline of viral RNA by day 28) [117]. Recently, it has
been demonstrated that increases in amino acid variations
in the NS3 protein of HCV genotypes 1a, 1b, 3a, and 3b
are associated with the response to Peg-IFN and ribavirin
combination therapy [118]. Amino acid variations within
the full-length NS3, particularly in protease and helicase
domains of NS3 of HCV genotype 1a, as well as the full-
length NS3/helicase domain of HCV genotype 1b from
responding patients treated with Peg-IFN and ribavirin
are significantly more frequent than those from treatment
failure groups [118]. In addition, use of an HCV replicon
cell line which was exposed to IFN-α and IFN-β revealed
that substitutions S1269Y, K1270R, and R1135K in NS3
protein were associated with IFN resistance [119]. The
possible reasons that may explain why these mutations
may lead to IFN resistance based on the fact that NS3 is
known as a bifunctional enzyme with serine protease
activity on the N-terminal domain and RNA helicase on
its C-terminal domain [120]. The NS3 helicase is essential
for HCV RNA replication and also plays a role in viral
particle assembly [121]. Conceivably, amino acid substitu-
tions in this region or particular position may affect the
function of NS3 and contribute to the acquisition of IFN
resistance. Correspondingly, Numba et al. [119] also
described these amino acid substitutions of S1269Y,
K1270R, and R1135K in the NS3 may contribute to the
acquisition of IFN resistance. To clarify these points,
further analysis, such as the characterization of HCV rep-
licon cells re-established by the transfection of these HCV
replicon RNAs into Huh7 cells, will be necessary [119].
HCV NS4B
Genetic analysis of HCV replicon cells resistance to
IFN-α and IFN-β exposure revealed that they all share
a single common amino acid substitution in the NS4B
(Q1737H) suggesting that these genetic alterations are
involved in their IFN-resistant phenotype [119]. In
addition, a rapid initial HCV RNA decline of ≥1.5 log
10 IU/mL at week 2 of IFN-based therapy is associated
with a higher frequency of non-conservative amino
acid exchanges within the complete NS4B protein
when compared to patients with a non-rapid HCV
RNA decline [122].
HCV NS5A
The initial data which supported a significant role of
amino acid variations within the NS5A protein of HCV
and the response to IFN therapy was first described by
Enomoto et al. in [123]. A correlation of a high number
of mutations in a IFN-α sensitivity determining region
(ISDR; codons 2209–2248) (Fig. 3) comprising 40 amino
acids within the C-terminal part of the NS5A protein
and SVR to IFN-α monotherapy in HCV genotype 1b
infected patients was described in Japan [124]. The
viruses obtained from patients who achieved an SVR
showed at least four mutations within the ISDR. Subse-
quently, the correlation of ISDR mutations with the
response to IFN treatment was investigated by different
groups in Japan, Europe and the United States. Many of
the studies were from Japan and were able to confirm
the strong correlation between ISDR mutations and
treatment response [114, 125–128]. However, contradict-
ory data have been reported from other parts of the
world, particularly from Europe and the United States.
The correlation of ISDR mutations with IFN-αsensitivity
was not able to be verified [111, 129–132]. The discrep-
ancy may be explained, at least in part, by host and viral
factors. It is well documented that host factors, particu-
larly the race of the subjects, are important factors
contributing to HCV treatment responsiveness [133]. In
addition to ISDR, the composition and number of muta-
tions found in the interferon and ribavirin resistance
determining region (IRRDR, residues 2334–2379, geno-
type 1) have been shown to be associated with response
to treatment [107, 134, 135]. A local accumulation of
mutations around the region so-called V3 (variable
region 3; codons 2356–2379) within the C-terminal part
of the NS5A was reported to correlate with the response
to Peg-IFN/ribavirin therapy in HCV genotype 1 isolates
[134, 136–138]. Furthermore, genetic analysis of HCV
replicon cells which were resistant to IFN treatment
revealed that particular substitutions in the NS5A pro-
tein (M2174V, T2319A/N, T2242N, F2256L) are associ-
ated with the resistance to IFN activity [119]. It has been
thought that NS5A blocks IFNs by interacting with PKR,
a double-strand RNA-dependent protein kinase. Amino
acid substitutions in the NS5A protein may exert the
function of PKR. The possibility is also considered that
some cellular factors, either alone or in combination
with viral factors, contributed to the acquisition of IFN
resistance [119].
HCV NS5B
The NS5B protein of HCV has been one of a number of
putative targets of nucleoside analogs, including ribavirin
[139]. It has been suggested that the HCV NS5B variant
F415Y conferred resistance to ribavirin in HCV genotype
1a infected patients [140]. Substitutions of E124K and
I85V identified in the NS5B protein are found to be
closely associated with early viral clearance at 8 weeks in
patients who were treated with IFN and ribavirin com-
bination therapy and were infected with the HCV geno-
type 1b and had a high level of viremia [141]. Moreover,
particular amino acid changes in the NS5B protein of
HCV have been shown to correlate with the outcomes
of combined-IFN plus ribavirin therapy. Sequence ana-
lysis of NS5B revealed that mutations at amino acid resi-
dues 309, 333, 338 and 355 of NS5B occurred more
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frequently in a group of patients exhibiting an SVR or
an end-of-treatment response than in a group of patients
showing a negative-response [142]. Furthermore, it has
been shown that mutations in NS5B, particularly in the
thumb domain and at amino acid position 389, correlate
with the viral load and response to IFN therapy of HCV
genotype 1b [143].
HCV mutations associated with the response to
antiviral agents
To date, several DAAs targeting the key components of
virus replication have been approved for the treatment
of HCV infection. Advances in using these drugs with or
without a combination of Peg-IFN/ribavirin have im-
proved SVR rates. However, resistance to antiviral agents
of HCV isolates have been documented. The patterns of
resistant variants or specific mutations are influenced by
multiple parameters including the specific inhibitor, viral
genotypes/subtypes and level of drug selective pressure
[144, 145]. In addition, some resistant mutations exist as
natural polymorphisms in each genotype/subtype. The
pattern of specific mutations resistant to each antiviral
agent are shown in Table 1.
Resistance to NS3/4A protease inhibitors
The FDA has approved three protease inhibitors, includ-
ing boceprevir, telaprevir and simeprevir for HCV geno-
type 1 treatment, still, these are not approved to be used
in monotherapy. A number of pre-treatment resistance
associated amino acid variants (RAVs) and polymor-
phisms have been shown to be associated with lower
responses to the treatment [146]. Both in vitro and in
vivo studies showed that several mutations in the NS3 at
positions 36, 155, 156, and 168 conferred broad cross-
resistance affecting all of these protease inhibitors
[146–148]. Boceprevir and telaprevir showed broad
cross-resistance. The RAVs most frequently associated
with boceprevir monotherapy are V36M, T54A/S,
V55A, R155K, A156S/T/V and V170A. Similar variants
are observed for telaprevir except for V55A and V170A
[144, 147, 149]. Moreover, the resistance mutation pro-
file is also influenced by HCV genotypes/subtypes. For
example, patients infected with HCV genotype 1a showed
main selective amino acid mutations at positions 36 and
155 whereas patients with HCV genotype 1b exhibited
selective mutations at positions 54, 55, 156 and 170
[144, 145, 150–152]. Substitution of D168Q is generally
found in HCV genotype 3 and this natural occurring
Fig. 3 HCV NS5A protein. Several regions within the NS5A proteins of HCV play a role in the IFN sensitivity of HCV including the interferon-sensitivity-
determining region (ISDR; codons 2209–2248 of HCV genome corresponding to amino acid residues 237–276 of NS5A protein), the interferon
and ribavirin resistance determining region (IRRDR; codons 2334–2379 or amino acid residues 362–407 of NS5A), the protein kinase R binding
domain (PKRBD; codons 2209–2274 or amino acid residues 237–302 of NS5A), and the variable region 3 (V3; codons 2353–2379 or amino acid
residues 381–407 of NS5A) [17, 98, 123, 135, 137]
Table 1 Amino acid substitutions associated with the resistance to different direct-acting antiviral agents
HCV protein targets DAAs Pattern of mutations
NS3/4A Boceprevir V36M/Aa, T54A/V/Sa, V55Aa, R155K/Ta, A156T/S/Va, V158I, D168N, V/I170A/T/L, L/M175L
Telapevir V36G/L/M/Aa, T54A/V/Sa, S122A/G/R, R155K/Ta, A156T/S/Va, D168A/H/T/V
Simeprevir V36M, F43S, Q80Ka, S122A/R, R155T/Ka, A156T/V, D168Q/A/H/T/V/Ea, V/I170A/T/L
NS5A Daclatasvir M28V/A/T, Q30R/E/H, L31F/V/Ma, Q54H/N/Y, H58D, Q62R/E, A92K/T, Y93H/N/Ca
Ledipasvir M28T, Q30R/H, L31V, Y93H/C
NS5B Sofosbuvir S282T, I434M, T179A, M289L, I293L, M434T, H479P, L159F/L320F
aAmino acid substitution represents the significant mutations that are clearly associated with reduced the response to treatment
DAAs direct-acting antiviral agents. Bolded amino acid substitutions indicate mutations frequently found to confer resistance to DAAs. Q80K for genotype 1a;
D168Q for genotype 3; Y93H for genotype 1b; S282T for genotypes 1a, 1b, and 2a. Adapted from reviews [144, 145, 148, 149, 157]
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mutation confers resistance to most protease inhibitors
[146, 147]. Simeprevir exhibits high antiviral activity
against HCV genotypes 2, 4, 5 and 6 whereas no effect
has been observed in genotype 3 [153]. The Q80K
mutation is a natural polymorphism detected at base-
line in the NS3 sequence. This variant is the most
prevalent baseline polymorphism observed in 19–48 %
of HCV genotype 1a and appears to be associated with
an impaired response to simeprevir [144, 153–155].
Resistance to NS5A inhibitors
NS5A inhibitors, daclatasvir (BMS-790052) and ledipasvir
(GS- 5885), target the binding to domain I of NS5A (amino
acid residues 1–213) and this binding leads to blocking of
RNA replication and virion assembly [156, 157]. The
potent antiviral activity of daclatasvir against HCV repli-
cons from different genotypes has been demonstrated
[158, 159]. However, higher rates of virologic responses to
daclatasvir have been observed among HCV genotype 1b
compared to genotype 1a [160, 161]. The resistance profile
of daclatasvir has been shown to be associated with several
amino acid changes within domain I of NS5A at positions
M28T, Q30R/H, L31V and Y93H for HCV genotype 1a
and L31H and Y93H for genotype 1b. These substitutions
have been identified in the in vitro replicon system and
show a strong correlation with those observed in the clin-
ical outcome [157, 162]. In the case of ledipasvir, baseline
pre-treatment mutations found in patients with HCV
genotype 1a before being exposed to this drug are M28T,
Q30R/H, L31M, Y93C/H. These mutations are associated
with reduced susceptibility to treatment response. In the
case of genotype 1b, Y93H is the most frequent substitu-
tion detected in 100 % of all patients [163].
Resistance to NS5B polymerase inhibitors
Sofosbuvir was recently approved by the FDA for the
treatment of chronic hepatitis C. Substitution of S282T in
NS5B has been reported to confer resistance to sofosbuvir
in vitro [164, 165]. By using a replicon system to investi-
gate the antiviral activity of sofosbuvir against different
HCV genotypes including 1a, 1b, 2a, 2b, and 3a, it was
revealed that the S282T mutation is the most common
mutation which conferred resistance to sofosbuvir in ge-
notypes 1a, 1b and 2a. For genotype 1a replicons, an add-
itional mutation I434M is observed in combination with
S282T. For genotype 2a, at least five additional mutations
(T179A, M289L, I293L, M434T, and H479P) have been
detected [164, 165]. Recently, mutations of L159F and
L320F in the NS5B polymerase that conferred resistance
to sofosbuvir have also been reported [166]. Sofosbuvir
has a very high barrier to resistance in patients as the re-
sistant mutants are very unfit.
Conclusions
Treatment of HCV infection has shown a dramatic
improvement in recent years since DAAs have been
introduced. A combination of antiviral agents with or
without IFN/ribavirin improves treatment success and
requires shorter treatment durations for patients in-
fected with diverse HCV genotypes. Although IFN-free
therapy has increased high SVR, this regimen is gener-
ally more expensive than IFN-based regimen. Hence,
some groups of patients may require IFN-containing
regimen. The results of IFN-based therapy is likely to
remain suboptimal due to host factors such as the host
immune response, IL28B phenotype, the presence or
absence of cirrhosis, and viral factors of viral load or ge-
notypes. Therefore, HCV mediated-IFN resistance may
remain an important factor in the failure of treatment in
certain parts of the world and needs to be explored.
Understanding of viral mutations and their associations
with the clinical outcomes of treatment as well as mech-
anisms of HCV mediated-IFN resistance should contrib-
ute to the improvement of therapeutic guidelines and
development of high efficacy and tailor made appropri-
ate regimens for chronic hepatitis C patients with differ-
ent genotypes and special cases.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KK drafted the initial manuscript and approved the final manuscript as
submitted; NM critically reviewed and revised the manuscript, and
approved the final manuscript as submitted.
Acknowledgements
This work was supported by the Faculty of Medicine, Chiang Mai University,
Chiang Mai, Thailand.
Received: 18 September 2015 Accepted: 9 December 2015
References
1. Lyra AC, Fan X, Di Bisceglie AM. Molecular biology and clinical implication
of hepatitis C virus. Braz J Med Biol Res. 2004;37:691–5.
2. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev
Microbiol. 2007;5:453–63.
3. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al.
The core protein of hepatitis C virus induces hepatocellular carcinoma in
transgenic mice. Nat Med. 1998;4:1065–7.
4. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, et al.
Hepatitis C virus core protein induces hepatic steatosis in transgenic mice.
J Gen Virol. 1997;78(Pt 7):1527–31.
5. Nunez O, Fernandez-Martinez A, Majano PL, Apolinario A, Gomez-Gonzalo
M, Benedicto I, et al. Increased intrahepatic cyclooxygenase 2, matrix
metalloproteinase 2, and matrix metalloproteinase 9 expression is
associated with progressive liver disease in chronic hepatitis C virus
infection: role of viral core and NS5A proteins. Gut. 2004;53:1665–72.
6. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, et al. Cell
entry of hepatitis C virus requires a set of co-receptors that include the
CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem.
2003;278:41624–30.
7. Nielsen SU, Bassendine MF, Burt AD, Bevitt DJ, Toms GL. Characterization of
the genome and structural proteins of hepatitis C virus resolved from
infected human liver. J Gen Virol. 2004;85:1497–507.
Kumthip and Maneekarn Virology Journal  (2015) 12:217 Page 8 of 12
8. Griffin SD, Beales LP, Clarke DS, Worsfold O, Evans SD, Jaeger J, et al. The p7
protein of hepatitis C virus forms an ion channel that is blocked by the
antiviral drug, Amantadine. FEBS Lett. 2003;535:34–8.
9. Pavlovic D, Neville DC, Argaud O, Blumberg B, Dwek RA, Fischer WB, et al.
The hepatitis C virus p7 protein forms an ion channel that is inhibited by
long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U S A.
2003;100:6104–8.
10. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. A second
hepatitis C virus-encoded proteinase. Proc Natl Acad Sci U S A.
1993;90:10583–7.
11. Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, et al. Two
distinct proteinase activities required for the processing of a putative
nonstructural precursor protein of hepatitis C virus. J Virol. 1993;67:4665–75.
12. Hijikata M, Mizushima H, Tanji Y, Komoda Y, Hirowatari Y, Akagi T, et al.
Proteolytic processing and membrane association of putative nonstructural
proteins of hepatitis C virus. Proc Natl Acad Sci U S A. 1993;90:10773–7.
13. Hijikata M, Shimotohno K. [Mechanisms of hepatitis C viral polyprotein
processing]. Uirusu. 1993;43:293–8.
14. Suzich JA, Tamura JK, Palmer-Hill F, Warrener P, Grakoui A, Rice CM, et al.
Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside
triphosphatase and comparison with the related pestivirus and flavivirus
enzymes. J Virol. 1993;67:6152–8.
15. Bartenschlager R, Lohmann V, Wilkinson T, Koch JO. Complex formation
between the NS3 serine-type proteinase of the hepatitis C virus and NS4A
and its importance for polyprotein maturation. J Virol. 1995;69:7519–28.
16. Gretton SN, Taylor AI, McLauchlan J. Mobility of the hepatitis C virus NS4B
protein on the endoplasmic reticulum membrane and membrane-
associated foci. J Gen Virol. 2005;86:1415–21.
17. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. The NS5A
protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem.
2004;279:48576–87.
18. Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding
domain of an essential component of the hepatitis C virus replicase. Nature.
2005;435:374–9.
19. Ivashkina N, Wolk B, Lohmann V, Bartenschlager R, Blum HE, Penin F, et al.
The hepatitis C virus RNA-dependent RNA polymerase membrane insertion
sequence is a transmembrane segment. J Virol. 2002;76:13088–93.
20. Schmidt-Mende J, Bieck E, Hugle T, Penin F, Rice CM, Blum HE, et al.
Determinants for membrane association of the hepatitis C virus RNA-
dependent RNA polymerase. J Biol Chem. 2001;276:44052–63.
21. Cruz-Rivera M, Carpio-Pedroza JC, Escobar-Gutierrez A, Lozano D, Vergara-
Castaneda A, Rivera-Osorio P, et al. Rapid hepatitis C virus divergence
among chronically infected individuals. J Clin Microbiol. 2013;51:629–32.
22. Honegger JR, Kim S, Price AA, Kohout JA, McKnight KL, Prasad MR, et al.
Loss of immune escape mutations during persistent HCV infection in
pregnancy enhances replication of vertically transmitted viruses. Nat Med.
2013;19:1529–33.
23. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al.
Expanded classification of hepatitis C virus into 7 genotypes and 67
subtypes: updated criteria and genotype assignment web resource.
Hepatology. 2014;59:318–27.
24. Agha S, Tanaka Y, Saudy N, Kurbanov F, Abo-Zeid M, El-Malky M, et al.
Reliability of hepatitis C virus core antigen assay for detection of viremia in
HCV genotypes 1, 2, 3, and 4 infected blood donors: a collaborative study
between Japan, Egypt, and Uzbekistan. J Med Virol. 2004;73:216–22.
25. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol
Infect. 2011;17:107–15.
26. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of
advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol.
2013;11:482–96.
27. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al.
The human scavenger receptor class B type I is a novel candidate receptor
for the hepatitis C virus. EMBO J. 2002;21:5017–25.
28. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding
of hepatitis C virus to CD81. Science. 1998;282:938–41.
29. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, et al.
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.
Nature. 2007;446:801–5.
30. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, et al. Human
occludin is a hepatitis C virus entry factor required for infection of mouse cells.
Nature. 2009;457:882–6.
31. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, et al. EGFR and
EphA2 are host factors for hepatitis C virus entry and possible targets for
antiviral therapy. Nat Med. 2011;17:589–95.
32. Lohmann V. Hepatitis C virus RNA replication. Curr Top Microbiol Immunol.
2013;369:167–98.
33. Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life
cycle: an update. J Hepatol. 2014;61:S3–s13.
34. Hepatitis C. [http://www.who.int/mediacentre/factsheets/fs164/en/]
35. Brass V, Moradpour D, Blum HE. Molecular virology of hepatitis C virus
(HCV): 2006 update. Int J Med Sci. 2006;3:29–34.
36. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity.
2006;25:373–81.
37. Heim MH, Thimme R. Innate and adaptive immune responses in HCV
infections. J Hepatol. 2014;61:S14–25.
38. Horner SM. Activation and evasion of antiviral innate immunity by hepatitis
C virus. J Mol Biol. 2014;426:1198–209.
39. Carithers Jr RL, Emerson SS. Therapy of hepatitis C: meta-analysis of
interferon alfa-2b trials. Hepatology. 1997;26:83s–8s.
40. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al.
Treatment of chronic non-A,non-B hepatitis with recombinant human alpha
interferon. A preliminary report. N Engl J Med. 1986;315:1575–8.
41. Te HS, Randall G, Jensen DM. Mechanism of action of ribavirin in the
treatment of chronic hepatitis C. Gastroenterol Hepatol (N Y).
2007;3:218–25.
42. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK,
et al. Interferon alfa-2b alone or in combination with ribavirin as initial
treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N
Engl J Med. 1998;339:1485–92.
43. McHutchison JG, Poynard T. Combination therapy with interferon plus
ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis.
1999;19 Suppl 1:57–65.
44. Scott LJ, Perry CM. Interferon-alpha-2b plus ribavirin: a review of its use in
the management of chronic hepatitis C. Drugs. 2002;62:507–56.
45. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in
treatment of hepatitis C. Nature. 2005;436:967–72.
46. Keating GM, Plosker GL. Peginterferon alpha-2a (40KD) plus ribavirin: a
review of its use in the management of patients with chronic hepatitis
C and persistently ‘normal’ ALT levels. Drugs. 2005;65:521–36.
47. Escudero A, Rodriguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.
Pegylated alpha-interferon-2a plus ribavirin compared with pegylated
alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis
C virus: prospective, non-randomized study. J Gastroenterol Hepatol.
2008;23:861–6.
48. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales Jr FL, et al.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N
Engl J Med. 2002;347:975–82.
49. Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, et al.
Peginterferon-alpha2a and ribavirin combination therapy in chronic
hepatitis C: a randomized study of treatment duration and ribavirin dose.
Ann Intern Med. 2004;140:346–55.
50. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R,
et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b
plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Lancet. 2001;358:958–65.
51. Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic
hepatitis C. Antiviral Res. 2003;59:1–11.
52. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to
treatment in patients with hepatitis C. Clin Microbiol Rev. 2007;20:23–38.
53. Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C
antiviral therapy response. World J Hepatol. 2015;7:1617–31.
54. Zhu Y, Chen S. Antiviral treatment of hepatitis C virus infection and factors
affecting efficacy. World J Gastroenterol. 2013;19:8963–73.
55. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M,
et al. Management of adverse effects of Peg-IFN and ribavirin therapy for
hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212–23.
56. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al.
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl
J Med. 2011;364:1207–17.
57. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR,
Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C
virus infection. N Engl J Med. 2011;364:2405–16.
Kumthip and Maneekarn Virology Journal  (2015) 12:217 Page 9 of 12
58. Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med.
2011;364:1195–206.
59. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir
for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28.
60. Kronenberger B, Zeuzem S. New developments in HCV therapy. J Viral
Hepat. 2012;19 Suppl 1:48–51.
61. Rosenquist A, Samuelsson B, Johansson PO, Cummings MD, Lenz O,
Raboisson P, et al. Discovery and development of simeprevir (TMC435), a
HCV NS3/4A protease inhibitor. J Med Chem. 2014;57:1673–93.
62. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily
simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-
naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology.
2013;58:1918–29.
63. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al.
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-
naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1):
a phase 3, randomised, double-blind, placebo-controlled trial. Lancet.
2014;384:403–13.
64. Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all? Nat
Rev Drug Discov. 2013;12:595–610.
65. Link JO, Taylor JG, Xu L, Mitchell M, Guo H, Liu H, et al. Discovery of ledipasvir
(GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of
hepatitis C virus infection. J Med Chem. 2014;57:2033–46.
66. DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, et al.
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med
Chem. 2014;57:2047–57.
67. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al.
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent
clinical effect. Nature. 2010;465:96–100.
68. Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, et al.
Daclatasvir for previously untreated chronic hepatitis C genotype-1
infection: a randomised, parallel-group, double-blind, placebo-controlled,
dose-finding, phase 2a trial. Lancet Infect Dis. 2012;12:671–7.
69. Chow J, Liu Y, Comstock K, Brandl M, Lin F, Li F, et al. Isolation and
identification of ester impurities in RG7128, an HCV polymerase inhibitor.
J Pharm Biomed Anal. 2010;53:710–6.
70. Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, et al.
Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2′-beta-C-methyluridine
nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med
Chem. 2010;53:7202–18.
71. Holler TP, Parkinson T, Pryde DC. Targeting the non-structural proteins of
hepatitis C virus: beyond hepatitis C virus protease and polymerase. Expert
Opin Drug Discov. 2009;4:293–314.
72. Koch U, Narjes F. Recent progress in the development of inhibitors of the
hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem.
2007;7:1302–29.
73. Gentile I, Buonomo AR, Borgia G. Dasabuvir: a non-nucleoside inhibitor of
NS5B for the treatment of hepatitis C virus infection. Rev Recent Clin Trials.
2014;9:115–23.
74. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al.
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N
Engl J Med. 2013;368:34–44.
75. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC,
et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N
Engl J Med. 2013;368:1878–87.
76. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al.
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-
naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-
label, randomised, multicentre phase 2 trial. Lancet. 2013;381:2100–7.
77. Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, et al.
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV
infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21:762–8.
78. Gritsenko D, Hughes G. Ledipasvir/Sofosbuvir (harvoni): improving options
for hepatitis C virus infection. P T. 2015;40:256–76.
79. Keating GM. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.
Drugs. 2015;75(6):675–85.
80. Gale Jr M. Effector genes of interferon action against hepatitis C virus.
Hepatology. 2003;37:975–8.
81. Gilmour KC, Reich NC. Signal transduction and activation of gene
transcription by interferons. Gene Expr. 1995;5:1–18.
82. Taylor DR, Shi ST, Lai MM. Hepatitis C virus and interferon resistance.
Microbes Infect. 2000;2:1743–56.
83. Hofmann WP, Zeuzem S, Sarrazin C. Hepatitis C virus-related resistance
mechanisms to interferon alpha-based antiviral therapy. J Clin Virol.
2005;32:86–91.
84. Gale Jr M, Foy EM. Evasion of intracellular host defence by hepatitis C virus.
Nature. 2005;436:939–45.
85. Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, et al. IFN-
alpha antagonistic activity of HCV core protein involves induction of
suppressor of cytokine signaling-3. FASEB J. 2003;17:488–90.
86. Shao RX, Zhang L, Peng LF, Sun E, Chung WJ, Jang JY, et al. Suppressor of
cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-
dependent manner. J Virol. 2010;84:6060–9.
87. de Lucas S, Bartolome J, Carreno V. Hepatitis C virus core protein down-
regulates transcription of interferon-induced antiviral genes. J Infect Dis.
2005;191:93–9.
88. Lin W, Choe WH, Hiasa Y, Kamegaya Y, Blackard JT, Schmidt EV, et al. Hepatitis
C virus expression suppresses interferon signaling by degrading STAT1.
Gastroenterology. 2005;128:1034–41.
89. Lin W, Kim SS, Yeung E, Kamegaya Y, Blackard JT, Kim KA, et al. Hepatitis C
virus core protein blocks interferon signaling by interaction with the STAT1
SH2 domain. J Virol. 2006;80:9226–35.
90. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the
interferon-inducible protein kinase PKR by HCV E2 protein. Science.
1999;285:107–10.
91. Horner SM, Gale Jr M. Regulation of hepatic innate immunity by hepatitis C
virus. Nat Med. 2013;19:879–88.
92. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A
cleaves mitochondrial antiviral signaling protein off the mitochondria to
evade innate immunity. Proc Natl Acad Sci U S A. 2005;102:17717–22.
93. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R,
et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is
targeted by hepatitis C virus. Nature. 2005;437:1167–72.
94. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, et al. Immune
evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the
Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A.
2005;102:2992–7.
95. Foy E, Li K, Sumpter Jr R, Loo YM, Johnson CL, Wang C, et al. Control of
antiviral defenses through hepatitis C virus disruption of retinoic acid-
inducible gene-I signaling. Proc Natl Acad Sci U S A. 2005;102:2986–91.
96. Foy E, Li K, Wang C, Sumpter Jr R, Ikeda M, Lemon SM, et al. Regulation of
interferon regulatory factor-3 by the hepatitis C virus serine protease.
Science. 2003;300:1145–8.
97. Xu J, Liu S, Xu Y, Tien P, Gao G. Identification of the nonstructural protein
4B of hepatitis C virus as a factor that inhibits the antiviral activity of
interferon-alpha. Virus Res. 2009;141:55–62.
98. Gale Jr MJ, Korth MJ, Katze MG. Repression of the PKR protein kinase by the
hepatitis C virus NS5A protein: a potential mechanism of interferon
resistance. Clin Diagn Virol. 1998;10:157–62.
99. Gale Jr MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, et al.
Evidence that hepatitis C virus resistance to interferon is mediated through
repression of the PKR protein kinase by the nonstructural 5A protein.
Virology. 1997;230:217–27.
100. Gong GZ, Cao J, Jiang YF, Zhou Y, Liu B. Hepatitis C virus non-structural 5A
abrogates signal transducer and activator of transcription-1 nuclear
translocation induced by IFN-alpha through dephosphorylation. World J
Gastroenterol. 2007;13:4080–4.
101. Kang SM, Won SJ, Lee GH, Lim YS, Hwang SB. Modulation of interferon
signaling by hepatitis C virus non-structural 5A protein: implication of
genotypic difference in interferon treatment. FEBS Lett.
2010;584:4069–76.
102. Kumthip K, Chusri P, Jilg N, Zhao L, Fusco DN, Zhao H, et al. Hepatitis C
virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon
signaling. J Virol. 2012;86:8581–91.
103. Lan KH, Lan KL, Lee WP, Sheu ML, Chen MY, Lee YL, et al. HCV NS5A inhibits
interferon-alpha signaling through suppression of STAT1 phosphorylation in
hepatocyte-derived cell lines. J Hepatol. 2007;46:759–67.
104. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Predictive
factors of virological non-response to interferon-ribavirin combination
therapy for patients infected with hepatitis C virus of genotype 1b and high
viral load. J Med Virol. 2006;78:83–90.
Kumthip and Maneekarn Virology Journal  (2015) 12:217 Page 10 of 12
105. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association
of amino acid substitution pattern in core protein of hepatitis C virus
genotype 1b high viral load and non-virological response to interferon-
ribavirin combination therapy. Intervirology. 2005;48:372–80.
106. Hayashi K, Katano Y, Ishigami M, Itoh A, Hirooka Y, Nakano I, et al. Mutations
in the core and NS5A region of hepatitis C virus genotype 1b and
correlation with response to pegylated-interferon-alpha 2b and ribavirin
combination therapy. J Viral Hepat. 2011;18:280–6.
107. El-Shamy A, Kim SR, Ide YH, Sasase N, Imoto S, Deng L, et al. Polymorphisms
of hepatitis C virus non-structural protein 5A and core protein and clinical
outcome of pegylated-interferon/ribavirin combination therapy.
Intervirology. 2012;55:1–11.
108. Funaoka Y, Sakamoto N, Suda G, Itsui Y, Nakagawa M, Kakinuma S, et al.
Analysis of interferon signaling by infectious hepatitis C virus clones with
substitutions of core amino acids 70 and 91. J Virol. 2011;85:5986–94.
109. Abid K, Quadri R, Negro F. Hepatitis C virus, the E2 envelope protein, and
alpha-interferon resistance. Science. 2000;287:1555.
110. Berg T, Mas Marques A, Hohne M, Wiedenmann B, Hopf U, Schreier E.
Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and
the dynamics of hepatitis C viremia decline during interferon alfa treatment.
Hepatology. 2000;32:1386–95.
111. Murphy MD, Rosen HR, Marousek GI, Chou S. Analysis of sequence
configurations of the ISDR, PKR-binding domain, and V3 region as
predictors of response to induction interferon-alpha and ribavirin therapy in
chronic hepatitis C infection. Dig Dis Sci. 2002;47:1195–205.
112. Sarrazin C, Kornetzky I, Ruster B, Lee JH, Kronenberger B, Bruch K, et al.
Mutations within the E2 and NS5A protein in patients infected with
hepatitis C virus type 3a and correlation with treatment response.
Hepatology. 2000;31:1360–70.
113. Saito T, Ito T, Ishiko H, Yonaha M, Morikawa K, Miyokawa A, et al. Sequence
analysis of PePHD within HCV E2 region and correlation with resistance of
interferon therapy in Japanese patients infected with HCV genotypes 2a
and 2b. Am J Gastroenterol. 2003;98:1377–83.
114. Ukai K, Ishigami M, Yoshioka K, Kawabe N, Katano Y, Hayashi K, et al.
Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha
phosphorylation homology domain and interferon sensitivity determining
region of nonstructural 5A of hepatitis C virus 1b: their correlation with
response to interferon monotherapy and viral load. World J Gastroenterol.
2006;12:3722–8.
115. Serre SB, Krarup HB, Bukh J, Gottwein JM. Identification of alpha interferon-
induced envelope mutations of hepatitis C virus in vitro associated with
increased viral fitness and interferon resistance. J Virol. 2013;87:12776–93.
116. Sarrazin C, Mihm U, Herrmann E, Welsch C, Albrecht M, Sarrazin U, et al.
Clinical significance of in vitro replication-enhancing mutations of the
hepatitis C virus (HCV) replicon in patients with chronic HCV infection.
J Infect Dis. 2005;192:1710–9.
117. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, et al. Pretreatment
sequence diversity differences in the full-length hepatitis C virus open
reading frame correlate with early response to therapy. J Virol.
2007;81:8211–24.
118. Chusri P, Kumthip K, Pantip C, Thongsawat S, O’Brien A, Maneekarn N.
Influence of amino acid variations in the NS3, NS4A and NS4B of HCV
genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon
and ribavirin combination therapy. Virus Res. 2015;196:37–43.
119. Numba K, Naka K, Dansako H, Nozaki A, Ikeda M, Shiratori Y, et al.
Establishment of hepatitis C virus replicon cell lines possessing interferon-
resistant phenotype. Biochem Biophys Res Commun. 2004;323:299–309.
120. Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, et al.
Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J Viral
Hepat. 2011;18:305–15.
121. Horner SM, Park HS, Gale Jr M. Control of innate immune signaling and
membrane targeting by the Hepatitis C virus NS3/4A protease are governed
by the NS3 helix alpha0. J Virol. 2012;86:3112–20.
122. Welker MW, Hofmann WP, Welsch C, von Wagner M, Herrmann E, Lengauer
T, et al. Correlation of amino acid variations within nonstructural 4B protein
with initial viral kinetics during interferon-alpha-based therapy in HCV-1b-
infected patients. J Viral Hepat. 2007;14:338–49.
123. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C,
et al. Comparison of full-length sequences of interferon-sensitive and
resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino
acid substitutions in the NS5A region. J Clin Invest. 1995;96:224–30.
124. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C,
et al. Mutations in the nonstructural protein 5A gene and response to
interferon in patients with chronic hepatitis C virus 1b infection. N Engl J
Med. 1996;334:77–81.
125. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y,
et al. Pretreatment virus load and multiple amino acid substitutions in the
interferon sensitivity-determining region predict the outcome of interferon
treatment in patients with chronic genotype 1b hepatitis C virus infection.
Hepatology. 1997;25:745–9.
126. Murayama M, Katano Y, Nakano I, Ishigami M, Hayashi K, Honda T, et al. A
mutation in the interferon sensitivity-determining region is associated with
responsiveness to interferon-ribavirin combination therapy in chronic
hepatitis patients infected with a Japan-specific subtype of hepatitis C virus
genotype 1B. J Med Virol. 2007;79:35–40.
127. Shen C, Hu T, Shen L, Gao L, Xie W, Zhang J. Mutations in ISDR of NS5A
gene influence interferon efficacy in Chinese patients with chronic hepatitis
C virus genotype 1b infection. J Gastroenterol Hepatol. 2007;22:1898–903.
128. Watanabe H, Enomoto N, Nagayama K, Izumi N, Marumo F, Sato C, et al.
Number and position of mutations in the interferon (IFN) sensitivity-
determining region of the gene for nonstructural protein 5A correlate
with IFN efficacy in hepatitis C virus genotype 1b infection. J Infect Dis.
2001;183:1195–203.
129. Chung RT, Monto A, Dienstag JL, Kaplan LM. Mutations in the NS5A region
do not predict interferon-responsiveness in american patients infected with
genotype 1b hepatitis C virus. J Med Virol. 1999;58:353–8.
130. Duverlie G, Khorsi H, Castelain S, Jaillon O, Izopet J, Lunel F, et al. Sequence
analysis of the NS5A protein of European hepatitis C virus 1b isolates and
relation to interferon sensitivity. J Gen Virol. 1998;79(Pt 6):1373–81.
131. Munoz de Rueda P, Casado J, Paton R, Quintero D, Palacios A, Gila A, et al.
Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis
C virus genotype 1 and their relationships to pegylated interferon-ribavirin
treatment responses. J Virol. 2008;82:6644–53.
132. Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of
European hepatitis C virus isolates and response to interferon alfa.
Hepatology. 1997;25:740–4.
133. Pascu M, Martus P, Hohne M, Wiedenmann B, Hopf U, Schreier E, et al.
Sustained virological response in hepatitis C virus type 1b infected patients
is predicted by the number of mutations within the NS5A-ISDR: a meta-
analysis focused on geographical differences. Gut. 2004;53:1345–51.
134. El-Shamy A, Sasayama M, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, et al.
Prediction of efficient virological response to pegylated interferon/ribavirin
combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A
antibodies in pre-treatment sera. Microbiol Immunol. 2007;51:471–82.
135. Kozuka R, Enomoto M, Hai H, Ogawa T, Nakaya M, Hagihara A, et al.
Changes in sequences of core region, interferon sensitivity-determining
region and interferon and ribavirin resistance-determining region of
hepatitis C virus genotype 1 during interferon-alpha and ribavirin therapy,
and efficacy of retreatment. Hepatol Res. 2012;42:1157–67.
136. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence
variation in hepatitis C virus nonstructural protein 5A predicts clinical
outcome of pegylated interferon/ribavirin combination therapy. Hepatology.
2008;48:38–47.
137. Kumthip K, Pantip C, Chusri P, Thongsawat S, O’Brien A, Nelson KE, et al.
Correlation between mutations in the core and NS5A genes of hepatitis C
virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon
and ribavirin combination therapy. J Viral Hepat. 2011;18:e117–125.
138. Nousbaum J, Polyak SJ, Ray SC, Sullivan DG, Larson AM, Carithers Jr RL, et al.
Prospective characterization of full-length hepatitis C virus NS5A
quasispecies during induction and combination antiviral therapy. J Virol.
2000;74:9028–38.
139. Lohmann V, Korner F, Herian U, Bartenschlager R. Biochemical properties of
hepatitis C virus NS5B RNA-dependent RNA polymerase and identification
of amino acid sequence motifs essential for enzymatic activity. J Virol.
1997;71:8416–28.
140. Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, Milstein SL, et al. Identification
of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin
monotherapy. Hepatology. 2003;38:869–78.
141. Kumagai N, Takahashi N, Kinoshita M, Tsunematsu S, Tsuchimoto K, Saito
H, et al. Polymorphisms of NS5B protein relates to early clearance of
hepatitis C virus by interferon plus ribavirin: a pilot study. J Viral Hepat.
2004;11:225–35.
Kumthip and Maneekarn Virology Journal  (2015) 12:217 Page 11 of 12
142. Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, Kurosaki M, et al.
Mutations in the NS5B region of the hepatitis C virus genome correlate
with clinical outcomes of interferon-alpha plus ribavirin combination
therapy. J Gastroenterol Hepatol. 2005;20:1401–9.
143. Watanabe K, Yoshioka K, Yano M, Ishigami M, Ukai K, Ito H, et al. Mutations
in the nonstructural region 5B of hepatitis C virus genotype 1b: their
relation to viral load, response to interferon, and the nonstructural region
5A. J Med Virol. 2005;75:504–12.
144. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with
hepatitis C virus infection. Gastroenterology. 2010;138:447–62.
145. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract
Res Clin Gastroenterol. 2012;26:487–503.
146. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E.
Update on hepatitis C virus resistance to direct-acting antiviral agents.
Antiviral Res. 2014;108:181–91.
147. Kieffer TL, George S. Resistance to hepatitis C virus protease inhibitors. Curr
Opin Virol. 2014;8:16–21.
148. Preciado MV, Valva P, Escobar-Gutierrez A, Rahal P, Ruiz-Tovar K, Yamasaki L,
et al. Hepatitis C virus molecular evolution: transmission, disease progression
and antiviral therapy. World J Gastroenterol. 2014;20:15992–6013.
149. Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus
infection therapy. J Infect Dis. 2013;207 Suppl 1:S33–39.
150. Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, et al.
Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-
experienced patients receiving telaprevir-based therapy in clinical trials.
PLoS One. 2012;7:e34372.
151. Barnard RJ, Howe JA, Ogert RA, Zeuzem S, Poordad F, Gordon SC, et al.
Analysis of boceprevir resistance associated amino acid variants (RAVs) in
two phase 3 boceprevir clinical studies. Virology. 2013;444:329–36.
152. Ogert RA, Howe JA, Vierling JM, Kwo PY, Lawitz EJ, McCone J, et al.
Resistance-associated amino acid variants associated with boceprevir plus
pegylated interferon-alpha2b and ribavirin in patients with chronic hepatitis
C in the SPRINT-1 trial. Antivir Ther. 2013;18:387–97.
153. Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem
S, et al. Antiviral activity of TMC435 monotherapy in patients infected with
HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study. J Hepatol.
2012;56:1247–53.
154. Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents for
the treatment of chronic hepatitis C. Expert Opin Investig Drugs.
2013;22:1107–21.
155. Shepherd SJ, Abdelrahman T, MacLean AR, Thomson EC, Aitken C, Gunson
RN. Prevalence of HCV NS3 pre-treatment resistance associated amino acid
variants within a Scottish cohort. J Clin Virol. 2015;65:50–3.
156. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, et al. Modeling
shows that the NS5A inhibitor daclatasvir has two modes of action and
yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci
U S A. 2013;110:3991–6.
157. Lim PJ, Gallay PA. Hepatitis C NS5A protein: two drug targets within the
same protein with different mechanisms of resistance. Curr Opin Virol.
2014;8:30–7.
158. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the
hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.
Antimicrob Agents Chemother. 2010;54:3641–50.
159. Fridell RA, Wang C, Sun JH, O’Boyle 2nd DR, Nower P, Valera L, et al.
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus
nonstructural protein 5A replication complex inhibitor BMS-790052 in
humans: in vitro and in vivo correlations. Hepatology. 2011;54:1924–35.
160. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T,
Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or
untreated chronic HCV infection. N Engl J Med. 2014;370:211–21.
161. Wang C, Sun JH, O’Boyle 2nd DR, Nower P, Valera L, Roberts S, et al.
Persistence of resistant variants in hepatitis C virus-infected patients treated
with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents
Chemother. 2013;57:2054–65.
162. Asselah T. NS5A inhibitors: a new breakthrough for the treatment of chronic
hepatitis C. J Hepatol. 2011;54:1069–72.
163. Gao M. Antiviral activity and resistance of HCV NS5A replication complex
inhibitors. Curr Opin Virol. 2013;3:514–20.
164. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, et al.
Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of
hepatitis C virus. Antimicrob Agents Chemother. 2012;56:3359–68.
165. Gotte M. Resistance to nucleotide analogue inhibitors of hepatitis C virus
NS5B: mechanisms and clinical relevance. Curr Opin Virol. 2014;8:104–8.
166. Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, et al. In vivo
emergence of a novel mutant L159F/L320F in the NS5B polymerase confers
low-level resistance to the HCV polymerase inhibitors mericitabine and
sofosbuvir. J Infect Dis. 2014;209:668–75.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kumthip and Maneekarn Virology Journal  (2015) 12:217 Page 12 of 12
